Search

Your search keyword '"Hustache‐Mathieu, Laurent"' showing total 29 results
Start Over Author "Hustache‐Mathieu, Laurent"
29 results on '"Hustache‐Mathieu, Laurent"'

2. Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study).

Author

Lemaitre, Florian, Lagoutte‐Renosi, Jennifer, Gagnieu, Marie‐Claude, Parant, François, Venisse, Nicolas, Grégoire, Matthieu, Bouchet, Stéphane, Garraffo, Rodolphe, Lê, Minh P., Muret, Patrice, Comets, Emmanuelle, Solas, Caroline, Peytavin, Gilles, Chirouze, Catherine, Hustache‐Mathieu, Laurent, Gendrin, Vincent, Drobatcheff‐Thiebaut, Marie‐Christine, Foltzer, Adeline, Obry‐Roguet, Véronique, and Brégigeon, Sylvie

Subjects
DRUG monitoring, HIV-positive persons, HIV, DOLUTEGRAVIR, HEPATITIS C virus, VIRAL load, NON-nucleoside reverse transcriptase inhibitors
Abstract

Aims: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended as a switch option in virologically suppressed HIV patients. Literature suggests that virological failure with dual therapy could possibly relate to subtherapeutic drug concentrations. In this study, we aimed at describing the DTG and RPV trough plasma concentrations (Cmin) and plasma HIV‐1 RNA viral load (VL) during maintenance dual therapy. Methods: We performed a retrospective analysis of DTG and RPV therapeutic drug monitoring in people living with HIV/AIDS (PLWHA) with dual therapy in 9 French centres. DTG and RPV trough plasma concentrations were estimated using a Bayesian approach to predict Cmin. The relationship between the pharmacokinetics of DTG and RPV and VL > 50 copies (cp)/mL was explored using joint nonlinear mixed models. The frequency of subtherapeutic threshold (DTG Cmin below 640 ng/mL and RPV Cmin below 50 ng/mL) were compared between PLWHA presenting VL > 50 cp/mL or not during the study. Results: At baseline, 209 PLWHA were enrolled in the study. At week 48, 19 people living with HIV/AIDS (9.1%) discontinued their treatment and 15 PLWHA (7.1%) exhibited VL > 50 cp/mL. Six PLWHA out of 15 (40.0%) with VL > 50 cp/mL during the follow‐up had at least 1 Cmin below the respective thresholds while only 26/194 patients (13.4%) without virological replication had at least 1 concentration below the threshold (P =.015). Conclusion: A majority of PLWHA receiving DTG/RPV maintenance dual therapy demonstrated VL < 50 cp/mL but virological replication was more frequent in people living with HIV/AIDS with subtherapeutic Cmin. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

Author

Obry-Roguet, Véronique, Duvivier, Claudine, Lions, Caroline, Huleux, Thomas, Jacomet, Christine, Ferry, Tristan, Cheret, Antoine, Allavena, Clotilde, Bani-Sadr, Firouzé, Palich, Romain, Cabié, André, Pugliese, Pascal, Delobel, Pierre, Lamaury, Isabelle, Hustache-Mathieu, Laurent, Bregigeon, Sylvie, Makinson, Alain, Rey, David, Poizot-Martin, Isabelle, Hustache‐Mathieu, Laurent, Drobacheff‐Thiébaut, C., Foltzer, A., Bouiller, K., Hustache‐ Mathieu, L., Chirouze, C., LEPILLER, Q., Bozon, F., Babre, O, Brunel, A.S., Muret, P., Laurichesse, H., Lesens, O., Vidal, M., Mrozek, N., Aumeran, C., Baud, O., Corbin, V., Letertre‐Gibert, P., Casanova, S., Prouteau, J., Fabre, I., Curlier, E., Ouissa, R., Herrmann‐Storck, C., Tressieres, B., Bonijoly, T., Receveur, M.C., Boulard, F., Daniel, C., Clavel, C., Merrien, D., Perré, P., Guimard, T., Bollangier, O., Leautez, S., Morrier, M., Laine, L., Ader, F., Becker, A., Biron, F., Boibieux, A., Cotte, L., Miailhes, P., Perpoint, T., Roux, S., Triffault‐Fillit, C., Degroodt, S., Brochier, C., Valour, F., Chidiac, C., Ménard, A., Belkhir, A.Y., Colson, P., Dhiver, C., Madrid, A., Martin‐Degioanni, M., Meddeb, L., Mokhtari, M., Motte, A., Raoux, A., Ravaux, I., Tamalet, C., Tomei, C., Tissot Dupont, H., Zaegel‐Faucher, O., Obry‐Roguet, Véronique, Laroche, H, Orticoni, M., Soavi, M.J., Geneau de Lamarlière, P, Ressiot, E, Ducassou, M.J., Jaquet, I., Galie, S., Galinier, A., Martinet, P., Landon, M., Ritleng, A.S., Ivanova, A., Debreux, C., Poizot‐Martin, I., Abel, S., Cabras, O., Cuzin, L., Guitteaud, K., Illiaquer, M., Pierre‐François, S., Osei, L., Pasquier, J., Rome, K., Sidani, E., Turmel, JM, Varache, C., Atoui, N., Bistoquet, M., Delaporte, E., Le Moing, V., Meftah, N., Merle de Boever, C., Montes, B., Montoya Ferrer, A., Tuaillon, E., Reynes, J., André, M., Boyer, L., Bouillon, MP., Delestan, M., Rabaud, C., May, T., Hoen, B., Bernaud, C., Billaud, E., Biron, C., Bonnet, B., Bouchez, S., Boutoille, D., Brunet‐Cartier, C., Deschanvres, C., Hall, N., Morineau, P., Reliquet, V., Sécher, S., Cavellec, M., Soria, A., Paredes, E., Ferre, V., André‐Garnier, E., Rodallec, A., Lefebvre, M., Grossi, O., Aubry, O., Raffi, F., Breaud, S., Ceppi, C., Chirio, D., Cua, E., Dellamonica, P., Demonchy, E., De Monte, A., Durant, J., Etienne, C., Ferrando, S., Garraffo, R., Michelangeli, C., Mondain, V., Naqvi, A., Oran, N., Perbost, I., Pillet, S., Pradier, C., Prouvost‐Keller, B., Risso, K., Rio, V., Roger, PM., Rosenthal, E., Sausse, S., Touitou, I., Wehrlen‐Pugliese, S., Zouzou, G., Hocqueloux, L., Prazuck, T., Gubavu, C., Sève, A., Maka, A., Boulard, C., Thomas, G., Lerolle, N., Landman, R., Joly, V., Ghosn, J., Rioux, C., Lariven, S., Gervais, A., Lescure, F.X., Matheron, S., Louni, F., Julia, Z., Mackoumbou‐Nkouka, C., Le Gac, S., Charpentier, C., Descamps, D., Peytavin, G., Yazdanpanah, Y., Amazzough, K., Benabdelmoumen, G., Bossi, P., Cessot, G., Charlier, C., Consigny, P.H., Danion, F., Dureault, A., Goesch, J., Guery, R., Henry, B., Jidar, K., Lanternier, F., Loubet, P., Lortholary, O., Louisin, C., Lourenco, J., Parize, P., Pilmis, B., Touam, F, Valantin, M.A., Tubiana, R., Agher, R, Seang, S., Schneider, L., Blanc, C., Katlama, C., Berger, J.L., N'guyen, Y., Lambert, D., Kmiec, I., Hentzien, M., Brunet, A., Brodard, V., Bani‐Sadr, Firouze, Tattevin, P., Revest, M., Souala, F., Baldeyrou, M., Patrat‐Delon, S., Chapplain, J.M., Bénézit, F., Dupont, M., Poinot, M., Maillard, A., Pronier, C., Lemaitre, F., Guennoun, C., Poisson‐Vanier, M., Jovelin, T., Sinteff, J.P., Arvieux, C., Botelho‐Nevers, E., Gagneux‐Brunon, A., Frésard, Anne, Ronat, V., Lucht, F., Fischer, P., Partisani, M., Cheneau, C., Priester, M, Batard, ML, Bernard‐Henry, C, de Mautort, E, Fafi‐Kremer, S., Alvarez, M., Biezunski, N., Debard, A., Delpierre, C., Lansalot, P., Lelievre, L., Martin‐Blondel, G., Piffaut, M., Porte, L., Saune, K., Ajana, F., Aïssi, E., Alcaraz, I., Baclet, V., Bocket, L., Boucher, A., Choisy, P., Lafon‐Desmurs, B., Meybeck, A., Pradier, M., Robineau, O., Viget, N., Valette, M., Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Tourcoing, Département des Maladies Infectieuses et Tropicales [CHU Gabriel-Montpied, Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], Pathogénie des Staphylocoques – Staphylococcal Pathogenesis, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Services des maladies infectieuses [CH Turcoing], Centre Hospitalier de Tourcoing, Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), Alliance for International medical Action (ALIMA), Service de Maladies Infectieuses et Tropicales [Fort-de-France, Martinique], CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Service de Maladies Infectieuses [Nice], Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pointe-à-Pitre/Abymes [Guadeloupe], service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Universtié Yaoundé 1 [Cameroun]-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Laboratoire d'Ingénierie Circulation Transport (LICIT), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-École Nationale des Travaux Publics de l'État (ENTPE)-Université de Lyon, Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Universitaire de Besançon (CHU Besançon), Université libre de Bruxelles (ULB), Hôpital Gabriel Montpied, Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Clermont-Ferrand, Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), CHU Gabriel Montpied (CHU), CHU Clermont-Ferrand, CCLIN Sud-Est – Centre de Coordination de la Lutte contre les Infections Nosocomiales Sud-Est, Montpellier Research in Management (MRM), Université Montpellier 1 (UM1)-Université Paul-Valéry - Montpellier 3 (UPVM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Perpignan Via Domitia (UPVD)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM), Laboratoire Traitement et Communication de l'Information (LTCI), Télécom ParisTech-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Equipe 15, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon], Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Neurobiologie, plasticité tissulaire et métabolisme énergétique (NPTME), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), CECIL, Space Research Institute of the Russian Academy of Sciences (IKI), Russian Academy of Sciences [Moscow] (RAS), Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre IRD de Montpellier (IRD), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Bell Labs (BELL), Lucent Technologies, Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Centre hospitalier universitaire de Nantes (CHU Nantes), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Service des maladies infectieuses et tropicales [CHU Nantes], Plant Biomechanics Group, Botanischer Garten, Albert-Ludwigs-Universität Freiburg, Service de virologie [CHU Nantes], Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, Public Health Department, Hôpital de l'Archet, Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Infectious Diseases Department, Université Montpellier 1 (UM1), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Régional de recherche et de Formation à la prise en charge Clinique de Fann (CRCF), CHNU Fann, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Etudes Lasers Intenses et Applications (CELIA), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Pathogénie des infections systémiques (UMR_S 570), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses [CHU Pitié-Salêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Laboratoire d'aérologie (LA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Centre National de la Recherche Scientifique (CNRS), McGill University = Université McGill [Montréal, Canada], Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôpitaux Universitaires de Strasbourg (HUS), Service de pneumologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], CHU Pontchaillou [Rennes], SEV, Groupe d'Etudes et de Contrôle des Variétés et des Semences (GEVES), Service de virologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), University Hospital and University Jean Monnet, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Génomique métabolique (UMR 8030), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Virologie et pathogenèse virale (VPV), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut Pasteur [Paris] (IP), Centre Hospitalier Gustave Dron [Tourcoing], Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) (EA 7327), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Département d'Hématologie Clinique [CHU Nantes] (Hôtel-Dieu), Hôtel-Dieu de Nantes-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Maladies infectieuses et tropicales dans la Caraïbe (MAITC EA 4537), CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique [Fort de France]-Université des Antilles (UA), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre de Physiopathologie Toulouse Purpan (CPTP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Dermatologie et Maladies infectieuses [Pointe-à-Pitre], CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre de Gestion du Risque Infectieux Nosocomial [Pointe-à-Pitre] (CGRIN), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Infectious and Tropical Diseases Department [Montpellier], Institut de Recherche pour le Développement (IRD)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM), Dat'AIDS study group: C Drobacheff-Thiébaut, A Foltzer, K Bouiller, C Chirouze, Q Lepiller, F Bozon, O Babre, A S Brunel, P Muret, H Laurichesse, O Lesens, M Vidal, N Mrozek, C Aumeran, O Baud, V Corbin, P Letertre-Gibert, S Casanova, J Prouteau, I Fabre, E Curlier, R Ouissa, C Herrmann-Storck, B Tressieres, T Bonijoly, M C Receveur, F Boulard, C Daniel, C Clavel, D Merrien, P Perré, T Guimard, O Bollangier, S Leautez, M Morrier, L Laine, F Ader, A Becker, F Biron, A Boibieux, L Cotte, P Miailhes, T Perpoint, S Roux, C Triffault-Fillit, S Degroodt, C Brochier, F Valour, C Chidiac, A Ménard, A Y Belkhir, P Colson, C Dhiver, A Madrid, M Martin-Degioanni, L Meddeb, M Mokhtari, A Motte, A Raoux, I Ravaux, C Tamalet, C Toméi, H Tissot Dupont, O Zaegel-Faucher, H Laroche, M Orticoni, M J Soavi, P Geneau de Lamarlière, E Ressiot, M J Ducassou, I Jaquet, S Galie, A Galinier, P Martinet, M Landon, A S Ritleng, A Ivanova, C Debreux, S Abel, O Cabras, L Cuzin, K Guitteaud, M Illiaquer, S Pierre-François, L Osei, J Pasquier, K Rome, E Sidani, J M Turmel, C Varache, N Atoui, M Bistoquet, E Delaporte, V Le Moing, N Meftah, C Merle de Boever, B Montes, A Montoya Ferrer, E Tuaillon, J Reynes, M André, L Boyer, M P Bouillon, M Delestan, C Rabaud, T May, B Hoen, C Bernaud, E Billaud, C Biron, B Bonnet, S Bouchez, D Boutoille, C Brunet-Cartier, C Deschanvres, N Hall, T Jovelin, P Morineau, V Reliquet, S Sécher, M Cavellec, A Soria, E Paredes, V Ferré, E André-Garnier, A Rodallec, M Lefebvre, O Grossi, O Aubry, F Raffi, S Breaud, C Ceppi, D Chirio, E Cua, P Dellamonica, E Demonchy, A De Monte, J Durant, C Etienne, S Ferrando, R Garraffo, C Michelangeli, V Mondain, A Naqvi, N Oran, I Perbost, S Pillet, C Pradier, B Prouvost-Keller, K Risso, V Rio, P M Roger, E Rosenthal, S Sausse, I Touitou, S Wehrlen-Pugliese, G Zouzou, L Hocqueloux, T Prazuck, C Gubavu, A Sève, A Maka, C Boulard, G Thomas, C Goujard, Y Quertainmont, E Teicher, N Lerolle, O Deradji, A Barrail-Tran, R Landman, V Joly, J Ghosn, C Rioux, S Lariven, A Gervais, F X Lescure, S Matheron, F Louni, Z Julia, C Mackoumbou-Nkouka, S Le Gac, C Charpentier, D Descamps, G Peytavin, Y Yazdanpanah, K Amazzough, G Benabdelmoumen, P Bossi, G Cessot, C Charlier, P H Consigny, F Danion, A Dureault, J Goesch, R Guery, B Henry, K Jidar, F Lanternier, P Loubet, O Lortholary, C Louisin, J Lourenco, P Parize, B Pilmis, F Touam, M A Valantin, R Tubiana, R Agher, S Seang, L Schneider, C Blanc, C Katlama, J L Berger, Y N'Guyen, D Lambert, I Kmiec, M Hentzien, A Brunet, V Brodard, P Tattevin, M Revest, F Souala, M Baldeyrou, S Patrat-Delon, J M Chapplain, F Benezit, M Dupont, M Poinot, A Maillard, C Pronier, F Lemaitre, C Guennoun, M Poisson-Vanier, T Jovelin, J P Sinteff, C Arvieux, E Botelho-Nevers, A Gagneux-Brunon, A Frésard, V Ronat, F Lucht, P Fischer, M Partisani, C Cheneau, M Priester, M L Batard, C Bernard-Henry, E de Mautort, S Fafi-Kremer, M Alvarez, N Biezunski, A Debard, C Delpierre, P Lansalot, L Lelièvre, G Martin-Blondel, M Piffaut, L Porte, K Saune, F Ajana, E Aïssi, I Alcaraz, V Baclet, L Bocket, A Boucher, P Choisy, B Lafon-Desmurs, A Meybeck, M Pradier, O Robineau, N Viget, M Valette., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Institut Pasteur [Paris], Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Université Paul-Valéry - Montpellier 3 (UPVM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Perpignan Via Domitia (UPVD)-Université Montpellier 1 (UM1)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, and Dupuis, Christine

Subjects
0301 basic medicine, Pediatrics, medicine.medical_specialty, MESH: Sarcoma, Kaposi* / epidemiology, [SDV]Life Sciences [q-bio], 030106 microbiology, HIV Infections, Dermatology, Skin Infectiology, Venereology and Sexual Health, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), medicine, Humans, MESH: HIV Infections* / complications, 030212 general & internal medicine, Sarcoma, Kaposi, Retrospective Studies, Response rate (survey), MESH: Acquired Immunodeficiency Syndrome, MESH: Herpesvirus 8, Human, Acquired Immunodeficiency Syndrome, MESH: Humans, business.industry, Kaposi sarcoma, HIV, Retrospective cohort study, MESH: Retrospective Studies, MESH: HIV Infections* / drug therapy, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], medical dermatology, Regimen, Infectious Diseases, Clinical research, clinical research, Herpesvirus 8, Human, Cohort, oncology, Original Article, Sarcoma, business, Viral load, MESH: HIV Infections* / epidemiology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background - Although antiretroviral therapy (ART) has reduced the risk of Kaposi sarcoma (KS), KS cases still occur in HIV-infected people. Objective - To describe all KS cases observed between 2010 and 2015 in a country with high ART coverage. Methods - Retrospective study using longitudinal data from 44 642 patients in the French Dat'AIDS multicenter cohort. Patients' characteristics were described at KS diagnosis according to ART exposure and to HIV-plasma viral load (HIV-pVL) (≤50 or >50) copies/mL. Results - Among the 209 KS cases diagnosed during the study period, 33.2% occurred in ART naïve patients, 17.3% in ART-experienced patients and 49.5% in patients on ART, of whom 23% for more than 6 months. Among these patients, 24 (11.5%) had HIV-pVL ≤50 cp/mL, and 16 (66%) were treated with a boosted-PI-based regimen. The distribution of KS localization did not differ by ART status nor by year of diagnosis. Limitations - Data on human herpesvirus 8, treatment modalities for KS and response rate were not collected. Conclusion - Half of KS cases observed in the study period occurred in patients not on ART, reflecting the persistence of late HIV diagnosis. Factors associated with KS in patients on ART with HIV-pVL ≤50 cp/mL remain to be explored.

Published
2020

4. Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients

Author

Lagoutte-Renosi, Jennifer, primary, Flammang, Mylène, additional, Chirouze, Catherine, additional, Beck-Wirth, Geneviève, additional, Bozon, Fabienne, additional, Brunel, Anne-Sophie, additional, Drobacheff-Thiebaut, Marie-Christine, additional, Foltzer, Adeline, additional, Hustache-Mathieu, Laurent, additional, Kowalczyk, Jakub, additional, Michel, Catherine, additional, Davani, Siamak, additional, and Muret, Patrice, additional

Published
2021
Full Text
View/download PDF

8. Additional file 2: Figure S1. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Author

Virlogeux, Victor, Zoulim, Fabien, Pugliese, Pascal, Poizot-Martin, Isabelle, Marc-Antoine Valantin, Cuzin, Lise, Reynes, Jacques, Billaud, Eric, Huleux, Thomas, Firouze Bani-Sadr, Rey, David, FrĂŠsard, Anne, Jacomet, Christine, Duvivier, Claudine, Cheret, Antoine, Hustache-Mathieu, Laurent, Hoen, Bruno, AndrĂŠ CabiĂŠ, and Cotte, Laurent

Subjects
body regions, nervous system, fungi, virus diseases, digestive system diseases
Abstract

Schematic diagram of HCV transmission compartmental model considering potential HCV treatment during acute phase. (PDF 26 kb)

Published
2017
Full Text
View/download PDF

9. Additional file 4: Figure S3. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Author

Virlogeux, Victor, Zoulim, Fabien, Pugliese, Pascal, Poizot-Martin, Isabelle, Marc-Antoine Valantin, Cuzin, Lise, Reynes, Jacques, Billaud, Eric, Huleux, Thomas, Firouze Bani-Sadr, Rey, David, Frésard, Anne, Jacomet, Christine, Duvivier, Claudine, Cheret, Antoine, Hustache-Mathieu, Laurent, Hoen, Bruno, Cabié, André, and Cotte, Laurent

Subjects
virus diseases
Abstract

Projected prevalence of HIV-HCV coinfection over the next 10 years within each risk group assuming an annual treatment coverage of 30%. (PDF 1673 kb)

Published
2017
Full Text
View/download PDF

10. Additional file 8: Figure S7. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Author

Virlogeux, Victor, Zoulim, Fabien, Pugliese, Pascal, Poizot-Martin, Isabelle, Marc-Antoine Valantin, Cuzin, Lise, Reynes, Jacques, Billaud, Eric, Huleux, Thomas, Firouze Bani-Sadr, Rey, David, Frésard, Anne, Jacomet, Christine, Duvivier, Claudine, Cheret, Antoine, Hustache-Mathieu, Laurent, Hoen, Bruno, Cabié, André, and Cotte, Laurent

Subjects
virus diseases, digestive system diseases
Abstract

Projected prevalence of HIV-HCV coinfections over the next 10 years in IVDU considering a potential risk of HCV transmission between HIV-negative and HIV-positive individuals. (PDF 153 kb)

Published
2017
Full Text
View/download PDF

11. Additional file 5: Figure S4. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Author

Virlogeux, Victor, Zoulim, Fabien, Pugliese, Pascal, Poizot-Martin, Isabelle, Marc-Antoine Valantin, Cuzin, Lise, Reynes, Jacques, Billaud, Eric, Huleux, Thomas, Firouze Bani-Sadr, Rey, David, Frésard, Anne, Jacomet, Christine, Duvivier, Claudine, Cheret, Antoine, Hustache-Mathieu, Laurent, Hoen, Bruno, Cabié, André, and Cotte, Laurent

Subjects
body regions, nervous system, fungi, virus diseases
Abstract

Projected prevalence (rate) of HIV-HCV coinfections over the next 10 years within each risk groups. (PDF 528 kb)

Published
2017
Full Text
View/download PDF

12. Additional file 6: Figure S5. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Author

Virlogeux, Victor, Zoulim, Fabien, Pugliese, Pascal, Poizot-Martin, Isabelle, Marc-Antoine Valantin, Cuzin, Lise, Reynes, Jacques, Billaud, Eric, Huleux, Thomas, Firouze Bani-Sadr, Rey, David, FrĂŠsard, Anne, Jacomet, Christine, Duvivier, Claudine, Cheret, Antoine, Hustache-Mathieu, Laurent, Hoen, Bruno, AndrĂŠ CabiĂŠ, and Cotte, Laurent

Subjects
virus diseases, digestive system diseases
Abstract

Projected prevalence of HIV-HCV coinfections over the next 10Â years considering potential HCV treatment during acute phase among high risk MSM. (PDF 187 kb)

Published
2017
Full Text
View/download PDF

13. Additional file 3: Figure S2. of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Author

Virlogeux, Victor, Zoulim, Fabien, Pugliese, Pascal, Poizot-Martin, Isabelle, Marc-Antoine Valantin, Cuzin, Lise, Reynes, Jacques, Billaud, Eric, Huleux, Thomas, Firouze Bani-Sadr, Rey, David, FrĂŠsard, Anne, Jacomet, Christine, Duvivier, Claudine, Cheret, Antoine, Hustache-Mathieu, Laurent, Hoen, Bruno, AndrĂŠ CabiĂŠ, and Cotte, Laurent

Abstract

Goodness of fit of the compartmental model to prevalence data between 2012 and 2016 in each risk group (heterosexuals, IVDU, MSM and others). (PDF 34 kb)

Published
2017
Full Text
View/download PDF

14. Additional file 1: of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Author

Virlogeux, Victor, Zoulim, Fabien, Pugliese, Pascal, Poizot-Martin, Isabelle, Marc-Antoine Valantin, Cuzin, Lise, Reynes, Jacques, Billaud, Eric, Huleux, Thomas, Firouze Bani-Sadr, Rey, David, Frésard, Anne, Jacomet, Christine, Duvivier, Claudine, Cheret, Antoine, Hustache-Mathieu, Laurent, Hoen, Bruno, Cabié, André, and Cotte, Laurent

Subjects
virus diseases
Abstract

Appendix. Table S1. Extrapolated numbers of HIV-monoinfected patients by subgroups in France in the population under care on January 1, 2016. Table S2. Extrapolated numbers of HIV-HCV coinfected patients with detectable HCV-RNA by subgroups in France in the population under care on January 1, 2016. Table S3. Extrapolated numbers of HIV-infected patients successfully treated for HCV or after spontaneous HCV clearance by subgroups in France in the population under care on January 1, 2016. Table S4. Estimated numbers of HIV-HCV coinfected patients by subgroup in France in the HIV undiagnosed population. Table S5. Number of first HCV infection observed each year in the Dat’AIDs cohort and extended to the diagnosed HIV population in France by risk group. Table S6. Estimated numbers of HIV-HCV coinfected IVDU considering several proportions of external cases, observed reinfection rate in the Dat'AIDs cohort, and an annual treatment coverage of 30% over the next 10 years. Table S7. Estimated numbers of HIV-HCV coinfected IVDU considering several proportions of external cases, reinfection rate based on mean first infection rate observed in the Dat'AIDs cohort, and an annual treatment coverage of 30% over the next 10 years. (DOCX 44 kb)

Published
2017
Full Text
View/download PDF

15. Elvitegravir–Cobicistat–Emtricitabine–Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.

Author

Gantner, Pierre, Hessamfar, Mojgan, Souala, Mohamed Faouzi, Valin, Nadia, Simon, Anne, Ajana, Faiza, Bouvet, Elisabeth, Rouveix, Elisabeth, Cotte, Laurent, Bani-Sadr, Firouzé, Hustache-Mathieu, Laurent, Lebrette, Marie-Gisèle, Truchetet, François, Galempoix, Jean-Marie, Piroth, Lionel, Pellissier, Gérard, Muret, Patrice, Rey, David, and Group, E/C/F/TAF PEP Study

Subjects
HIV prevention, HIV infection risk factors, SEXUALLY transmitted disease diagnosis, COMBINATION drug therapy, CLINICAL trials, CONFIDENCE intervals, DRUGS, HIV infections, PATIENT compliance, QUALITY of life, RESEARCH funding, ANTI-HIV agents
Abstract

We evaluated an elvitegravir–cobicistat–emtricitabine–tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis. Clinical Trials Registration NCT02998320. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

16. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV

Author

Pradat, Pierre, primary, Huleux, Thomas, additional, Raffi, François, additional, Delobel, Pierre, additional, Valantin, Marc-Antoine, additional, Poizot-Martin, Isabelle, additional, Pugliese, Pascal, additional, Reynes, Jacques, additional, Rey, David, additional, Hoen, Bruno, additional, Cabie, André, additional, Bani-Sadr, Firouzé, additional, Cheret, Antoine, additional, Duvivier, Claudine, additional, Jacomet, Christine, additional, Fresard, Anne, additional, Hustache-Mathieu, Laurent, additional, and Cotte, Laurent, additional

Published
2018
Full Text
View/download PDF

17. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients – “En route for eradication”?

Author

Pradat, Pierre, primary, Pugliese, Pascal, additional, Poizot-Martin, Isabelle, additional, Valantin, Marc-Antoine, additional, Cuzin, Lise, additional, Reynes, Jacques, additional, Billaud, Eric, additional, Huleux, Thomas, additional, Bani-Sadr, Firouze, additional, Rey, David, additional, Frésard, Anne, additional, Jacomet, Christine, additional, Duvivier, Claudine, additional, Cheret, Antoine, additional, Hustache-Mathieu, Laurent, additional, Hoen, Bruno, additional, Cabié, André, additional, Cotte, Laurent, additional, Cotte, L., additional, Chidiac, C., additional, Ferry, T., additional, Ader, F., additional, Biron, F., additional, Boibieux, A., additional, Miailhes, P., additional, Perpoint, T., additional, Schlienger, I., additional, Lippmann, J., additional, Braun, E., additional, Koffi, J., additional, Longuet, C., additional, Guéripel, V., additional, Augustin-Normand, C., additional, Brochier, C., additional, Degroodt, S., additional, Pugliese, P., additional, Ceppi, C., additional, Cua, E., additional, Cottalorda, J., additional, Courjon, J., additional, Dellamonica, P., additional, Demonchy, E., additional, De Monte, A., additional, Durant, J., additional, Etienne, C., additional, Ferrando, S., additional, Fuzibet, J.G., additional, Garraffo, R., additional, Joulie, A., additional, Risso, K., additional, Mondain, V., additional, Naqvi, A., additional, Oran, N., additional, Perbost, I., additional, Pillet, S., additional, Prouvost-Keller, B., additional, Wehrlen-Pugliese, S., additional, Rosenthal, E., additional, Sausse, S., additional, Rio, V., additional, Roger, P.M., additional, Brégigeon, S., additional, Faucher, O., additional, Obry-Roguet, V., additional, Orticoni, M., additional, Soavi, M.J., additional, Geneau de Lamarlière, P., additional, Laroche, H., additional, Ressiot, E., additional, Carta, M., additional, Ducassou, M.J., additional, Jacquet, I., additional, Gallie, S., additional, Galinier, A., additional, Ritleng, A.S., additional, Ivanova, A., additional, Blanco-Betancourt, C., additional, Lions, C., additional, Debreux, C., additional, Poizot-Martin, I., additional, Agher, R., additional, Katlama, C., additional, Valantin, M.A., additional, Duvivier, C., additional, Lortholary, O., additional, Lanternier, F., additional, Charlier, C., additional, Rouzaud, C., additional, Aguilar, C., additional, Henry, B., additional, Lebeaux, D., additional, Cessot, G., additional, Gergely, A., additional, Consigny, P.H., additional, Touam, F., additional, Louisin, C., additional, Alvarez, M., additional, Biezunski, N., additional, Cuzin, L., additional, Debard, A., additional, Delobel, P., additional, Delpierre, C., additional, Fourcade, C., additional, Marchou, B., additional, Martin-Blondel, G., additional, Porte, M., additional, Mularczyk, M., additional, Garipuy, D., additional, Saune, K., additional, Lepain, I., additional, Marcel, M., additional, Puntis, E., additional, Atoui, N., additional, Casanova, M.L., additional, Faucherre, V., additional, Jacquet, J.M., additional, Le Moing, V., additional, Makinson, A., additional, Merle De Boever, C., additional, Montoya-Ferrer, A., additional, Psomas, C., additional, Reynes, J., additional, Raffi, F., additional, Allavena, C., additional, Billaud, E., additional, Biron, C., additional, Bonnet, B., additional, Bouchez, S., additional, Boutoille, D., additional, Brunet, C., additional, Jovelin, T., additional, Hall, N., additional, Bernaud, C., additional, Morineau, P., additional, Reliquet, V., additional, Aubry, O., additional, Point, P., additional, Besnier, M., additional, Larmet, L., additional, Hüe, H., additional, Pineau, S., additional, André-Garnier, E., additional, Rodallec, A., additional, Choisy, Ph., additional, Vandame, S., additional, Huleux, Th., additional, Ajana, F., additional, Alcaraz, I., additional, Baclet, V., additional, Huleux, T.H., additional, Melliez, H., additional, Viget, N., additional, Valette, M., additional, Aissi, E., additional, Allienne, Ch., additional, Meybeck, A., additional, Riff, B., additional, Bani-Sadr, F., additional, Rouger, C., additional, Berger, J.L., additional, N'Guyen, Y., additional, Lambert, D., additional, Kmiec, I., additional, Hentzien, M., additional, Lebrun, D., additional, Migault, C., additional, Rey, D., additional, Batard, M.L., additional, Bernard-Henry, C., additional, Cheneau, C., additional, de Mautort, E., additional, Fischer, P., additional, Partisani, M., additional, Priester, M., additional, Lucht, F., additional, Frésard, A., additional, Botelho-Nevers, E., additional, Gagneux-Brunon, A., additional, Cazorla, C., additional, Guglielminotti, C., additional, Daoud, F., additional, Lutz, M.F., additional, Jacomet, C., additional, Laurichesse, H., additional, Lesens, O., additional, Vidal, M., additional, Mrozek, N., additional, Corbin, V., additional, Aumeran, C., additional, Baud, O., additional, Casanova, S., additional, Coban, D., additional, Hustache-Mathieu, L., additional, Thiebaut-Drobacheff, M.C., additional, Foltzer, A., additional, Gendrin, V., additional, Bozon, F., additional, Chirouze, C., additional, Abel, S., additional, Cabié, A., additional, Césaire, R., additional, Santos, G. Dos, additional, Fagour, L., additional, Najioullah, F., additional, Ouka, M., additional, Pierre-François, S., additional, Pircher, M., additional, Rozé, B., additional, Hoen, B., additional, Ouissa, R., additional, and Lamaury, I., additional

Published
2017
Full Text
View/download PDF

18. Brill-Zinsser disease in Moroccan man, France, 2011

Author

Faucher, Jean-Frangois, Socolovschi, Cristina, Aubry, Camille, Chirouze, Catherine, Hustache-Mathieu, Laurent, Raoult, Didier, and Hoen, Bruno

Subjects
France -- Health aspects, Epidemics -- Research -- France, Moroccans -- Diagnosis -- Care and treatment, Typhoid fever -- Diagnosis -- Care and treatment, Health
Abstract

To the Editor: Epidemic typhus is caused by Rickettsia prowazekii and transmitted by human body lice. For centuries, it has been associated with overcrowding, cold weather, and poor hygiene. Brill-Zinsser [...]

Published
2012
Full Text
View/download PDF

19. Neisseria sicca Endocarditis Complicated by Intracranial and Popliteal Aneurysms in a Patient with a Bicuspid Aortic Valve

Author

Debellemanière, Guillaume, Chirouze, Catherine, Hustache-Mathieu, Laurent, Fournier, Damien, Biondi, Alessandra, and Hoen, Bruno

Subjects
Article Subject, cardiovascular system, cardiovascular diseases
Abstract

We report a case of infective endocarditis due to Neisseria sicca complicated by intracranial and popliteal aneurysms and hepatic and splenic infarcts in a patient with a bicuspid aortic valve. No predisposing factor other than poor dental condition was found. The patient fully recovered after antibiotic therapy, aortic and mitral valve replacement, endovascular occlusion of the middle-cerebral artery aneurysm, and surgical treatment of the popliteal artery aneurysm.

Published
2013
Full Text
View/download PDF

20. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.

Author

Virlogeux, Victor, Zoulim, Fabien, Pugliese, Pascal, Poizot-Martin, Isabelle, Valantin, Marc-Antoine, Cuzin, Lise, Reynes, Jacques, Billaud, Eric, Huleux, Thomas, Bani-Sadr, Firouze, Rey, David, Frésard, Anne, Jacomet, Christine, Duvivier, Claudine, Cheret, Antoine, Hustache-Mathieu, Laurent, Hoen, Bruno, Cabié, André, Cotte, Laurent, and Dat’AIDS Study Group

Subjects
HIV infections, HEPATITIS C virus, MIXED infections, EPIDEMIOLOGY, ANTIVIRAL agents
Abstract

Background: HCV treatment uptake has drastically increased in HIV-HCV coinfected patients in France since direct-acting antiviral (DAA) treatment approval, resulting in HCV cure in 63% of all HIV-HCV patients by the end of 2015. We investigated the impact of scaling-up DAA on HCV prevalence in the whole HIV population and in various risk groups over the next 10 years in France using a transmission dynamic compartmental model.Methods: The model was based on epidemiological data from the French Dat'AIDS cohort. Eight risk groups were considered, including high-risk (HR) and low-risk (LR) men who have sex with men (MSM) and male/female heterosexuals, intra-venous drug users, or patients from other risk groups. The model was calibrated on prevalence and incidence data observed in the cohort between 2012 and 2015.Results: On January 1, 2016, 156,811 patients were registered as infected with HIV in France (24,900 undiagnosed patients) of whom 7938 (5.1%) had detectable HCV-RNA (722 undiagnosed patients). Assuming a treatment coverage (TC) rate of 30%/year (i.e., the observed rate in 2015), model projections showed that HCV prevalence among HIV patients is expected to drop to 0.81% in 2026. Sub-analyses showed a similar decrease of HIV-HCV prevalence in most risk groups, including LR MSM. Due to higher infection and reinfection rates, predicted prevalence in HR MSM remained stable from 6.96% in 2016 to 6.34% in 2026. Increasing annual TC rate in HR MSM to 50/70% would decrease HCV prevalence in this group to 2.35/1.25% in 2026. With a 30% TC rate, undiagnosed patients would account for 34% of HCV infections in 2026.Conclusions: Our model suggests that DAA could nearly eliminate coinfection in France within 10 years for most risk groups, including LR MSM. Elimination in HR MSM will require increased TC. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

22. Syndrome de reconstitution immunitaire tardif à Pneumocystis jiroveci chez une patiente VIH

Author

Bellanger , Anne-Pauline, Hustache-Mathieu , Laurent, Ranfaing , Elisabeth, Millon , Laurence, Hoen , Bruno, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
[SDE.ES]Environmental Sciences/Environmental and Society, ComputingMilieux_MISCELLANEOUS, [ SDE.ES ] Environmental Sciences/Environmental and Society
Abstract

National audience

Published
2009

23. [Atypical course of falciparum malaria in an asplenic patient]

Author

Faucher , Jean-François, Créantor , Carole, Hustache-Mathieu , Laurent, Chirouze , Catherine, Millon , Laurence, Hoen , Bruno, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre National de la Recherche Scientifique ( CNRS ), services de maladies infectieuses, CHU J Minjoz, Besançon, Ministère de la santé, Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques

Subjects
Adult, Male, MESH: Quinine, MESH : Recurrence, MESH : Male, MESH : Treatment Outcome, MESH: Splenectomy, MESH : Malaria, Falciparum, Antimalarials, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Recurrence, MESH : Quinine, parasitic diseases, Humans, Malaria, Falciparum, MESH: Travel, MESH : Splenectomy, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, [ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, MESH: Treatment Outcome, MESH : Mefloquine, Travel, MESH: Humans, Quinine, MESH: Malaria, Falciparum, MESH : Humans, MESH: Adult, MESH : Adult, MESH: Antimalarials, MESH: Male, MESH: Recurrence, Mefloquine, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH : Travel, Treatment Outcome, Splenectomy, MESH : Antimalarials, MESH: Mefloquine
Abstract

International audience; INTRODUCTION: The aim of treatment for falciparum malaria therapy is to achieve adequate clinical and parasitologic response within 7 days of starting treatment, with no subsequent relapse. We report and discuss the atypical course of a falciparum malaria attack observed in an asplenic patient returning from Burkina-Faso. CASE: This 34-year-old man was hospitalized for severe malaria and treated for 7 days with quinine, as an inpatient. Adequate early clinical response was observed. Twenty days after the end of the quinine course, he was readmitted for uncomplicated falciparum malaria. Inpatient treatment used mefloquine this time. Clinical response was adequate, but the blood smear was still positive 10 days later. It was decided not to administer further treatment at that time. Subsequent clinical and parasitologic assessments 1 month and 3 months later showed the patient was cured. CONCLUSION: This report illustrates the critical role played by the spleen in parasite clearance. Clinical and parasitologic assessments are essential after treatment of asplenic patients for falciparum malaria.

Published
2006

26. CORONARY CALCIFICATION IN HIV-INFECTED PATIENTS, ASSESSED BY CORONARY ARTERY CALCIUM SCORE (CACS): THE VIHCAC STUDY

Author

Chopard, Romain, primary, Foltzer, Adeline, additional, Jehl, Jerome, additional, Drobacheff-Thiebaut, Christine, additional, Chirouze, Catherine, additional, Hustache-Mathieu, Laurent, additional, Gil, Helder, additional, Faller, Jean-Pierre, additional, Kastler, Bruno, additional, Hoen, Bruno, additional, and Schiele, Francois, additional

Published
2011
Full Text
View/download PDF

28. Iatrogenic recurrence of Kaposi sarcoma induced by the pharmacological interaction between periarticular injection of corticosteroids and ritonavir in a HIV‐infected patient.

Author

Fakih, Olivier, Drobacheff‐Thiébaut, Christine, Hustache‐Mathieu, Laurent, Puzenat, Eve, Sérézal, Irène Gallais, and Aubin, François

Subjects
CORTICOSTEROIDS, KAPOSI'S sarcoma, RITONAVIR, IATROGENIC diseases, INJECTIONS, ADRENAL insufficiency
Abstract

Iatrogenic recurrence of Kaposi sarcoma induced by the pharmacological interaction between periarticular injection of corticosteroids and ritonavir in a HIV-infected patient Dear Editor Iatrogenic Kaposi sarcoma (KS) is usually associated with immunosuppressive drugs such as corticosteroids, azathioprine, methotrexate and cyclosporine, for lupus erythematosus, kidney transplantation, temporal arteritis, widespread psoriasis, pemphigus and bullous pemphigoid, atopic dermatitis and malignancies.1 We report a case of a iatrogenic KS induced by the pharmacological interaction of a corticosteroid with an inhibitor of the cytochrome P450. High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy. [Extracted from the article]

Published
2021
Full Text
View/download PDF

29. [Atypical course of falciparum malaria in an asplenic patient].

Author

Faucher JF, Créantor C, Hustache-Mathieu L, Chirouze C, Millon L, and Hoen B

Subjects
Adult, Humans, Male, Mefloquine therapeutic use, Quinine therapeutic use, Recurrence, Travel, Treatment Outcome, Antimalarials therapeutic use, Malaria, Falciparum drug therapy, Splenectomy
Abstract

Introduction: The aim of treatment for falciparum malaria therapy is to achieve adequate clinical and parasitologic response within 7 days of starting treatment, with no subsequent relapse. We report and discuss the atypical course of a falciparum malaria attack observed in an asplenic patient returning from Burkina-Faso., Case: This 34-year-old man was hospitalized for severe malaria and treated for 7 days with quinine, as an inpatient. Adequate early clinical response was observed. Twenty days after the end of the quinine course, he was readmitted for uncomplicated falciparum malaria. Inpatient treatment used mefloquine this time. Clinical response was adequate, but the blood smear was still positive 10 days later. It was decided not to administer further treatment at that time. Subsequent clinical and parasitologic assessments 1 month and 3 months later showed the patient was cured., Conclusion: This report illustrates the critical role played by the spleen in parasite clearance. Clinical and parasitologic assessments are essential after treatment of asplenic patients for falciparum malaria.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results